Your search returned 5 results.

Sort
Results
1.
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
  • Swain, Sandra M
PMID:
  • 24129974
Year: 2013
Citation:
  • Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
2.
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors:
  • Swain, Sandra M
PMID:
  • 24869931
Year: 2014
Citation:
  • Oncologist. 19(7):693-701, 2014 Jul.
Institution:
  • Washington Cancer Institute
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM
3.
Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors:
  • Swain, Sandra M
PMID:
  • 23868905
Year: 2013
Citation:
  • Annals of Oncology. 24(10):2630-5, 2013 Oct.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM
4.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
  • Swain, Sandra M
PMID:
  • 23602601
Year: 2013
Citation:
  • Lancet Oncology. 14(6):461-71, 2013 May.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
5.
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors:
  • Swain, Sandra M
PMID:
  • 24095300
Year: 2013
Citation:
  • Lancet Oncology. 14(12):1183-92, 2013 Nov.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Comparative Study
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N
Pages

Powered by Koha